BTZ inhibits β5 and β1 proteasome subunits at concentrations above 100 nM, while CFZ inhibits β5 and β2 at concentrations above 3,000 nM in MM cells after 1 h of treatment.4 This evidence concerns the gene CASC3 and Miyoshi myopathy.